Patterns of improvement following initial response in patients treated with naxitamab for relapsed/refractory high-risk neuroblastoma

被引：0
|
作者：
Mora, Jaume
Chan, Godfrey C.
Morgenstern, Daniel A.
Amoroso, Loredana
Nysom, Karsten
Faber, Joerg
Wingerter, Arthur
Bear, Melissa
Rubio-San-Simon, Alba
Tornoe, Karen
Duering, Maria
Kushner, Brian H.
机构：
[1] Hosp St Joan de Deu, Pediat Canc Ctr Barcelona, Barcelona, Spain
[2] Queen Mary Hosp, Hong Kong, Peoples R China
[3] Univ Hong Kong, Hong Kong Childrens Hosp, Pokfulam, Hong Kong, Peoples R China
[4] Hosp Sick Children, Toronto, ON, Canada
[5] IRCCS Ist Giannina Gaslini, Genoa, Italy
[6] Copenhagen Univ Hosp, Rigshosp, Copenhagen, Denmark
[7] Johannes Gutenberg Univ Mainz, Univ Med Ctr, Ctr Pediat & Adolescent Med, Mainz, Germany
[8] Riley Hosp Children, Indianapolis, IN USA
[9] Hosp Infantil Univ Nino Jesus, Madrid, Spain
[10] Y mAbs AS, Horsholm, Denmark
[11] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
10033
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Disease control in patients treated with naxitamab for refractory/relapsed high-risk neuroblastoma
    Mora, Jaume
    Chan, Godfrey C.
    Morgenstern, Daniel A.
    Amoroso, Loredana
    Nysom, Karsten
    Faber, Joerg
    Wingerter, Arthur
    Bear, Melissa
    Rubio-San-Simon, Alba
    Tornoe, Karen
    Koep, Sharif
    During, Maria
    Kushner, Brian H.
    CANCER RESEARCH, 2024, 84 (17)
  • [2] Naxitamab chemo-immunotherapy regimens other than with irinotecan/temozolomide for patients with relapsed/refractory high-risk neuroblastoma
    Larrosa, Crstina
    Simao Rafael, Margarida
    Pablo Munoz, Juan
    Gorostegui, Maite
    Castaneda Heredia, Alicia
    Garraus, Moira
    Mora, Jaume
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [3] Naxitamab-related adverse events within and across treatment cycles in patients with relapsed/refractory (R/R) high-risk neuroblastoma
    Mora, Jaume
    Chan, Godfrey C.
    Morgenstern, Daniel A.
    Amoroso, Loredana
    Nysom, Karsten
    Faber, Joerg
    Wingerter, Arthur
    Bear, Melissa
    Rubio-San-Simon, Alba
    Eldridge, James
    Tornoe, Karen
    Duering, Maria
    Kushner, Brian H.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [4] Naxitamab treatment for relapsed or refractory high-risk neuroblastoma: Outcomes from the first prespecified analyses of the Pivotal 201 Trial
    Mora, J.
    Bear, M.
    Chan, G.
    Morgenstern, D. A.
    Nysom, K.
    Tornoe, K.
    Sorensen, P. S.
    Kushner, B.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S956 - S956
  • [5] Naxitamab (NAX) treatment for refractory/relapsed (R/R) high-risk neuroblastoma (HRNB): Response data and efficacy in patient (pt) subgroups.
    Mora, Jaume
    Chan, Godfrey Chi-Fung
    Morgenstern, Daniel A.
    Nysom, Karsten
    Bear, Melissa
    Tornoe, Karen
    Sorensen, Per Settergren
    Kushner, Brian H.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [6] Oxaliplatin and Doxorubicin for Relapsed or Refractory High-Risk Neuroblastoma
    Tran, Hung C.
    Marachelian, Araz
    Venkatramani, Rajkumar
    Jubran, Rima F.
    Mascarenhas, Leo
    PEDIATRIC HEMATOLOGY AND ONCOLOGY, 2015, 32 (01) : 26 - 31
  • [7] OXALIPLATIN AND DOXORUBICIN TREATMENT FOR RELAPSED AND REFRACTORY HIGH-RISK NEUROBLASTOMA
    Hung Tran
    Marachelian, Araz
    Venkatramani, Rajkumar
    Jubran, Rima
    Mascarenhas, Leo
    PEDIATRIC BLOOD & CANCER, 2013, 60 : S73 - S73
  • [8] Hypofractionated Palliative Radiotherapy for Relapsed and Refractory High-Risk Neuroblastoma
    Koelker-Wolfe, E. R.
    Marcus, K. J.
    Dubois, S. G.
    Shusterman, S.
    Ioakeim-Ioannidou, M.
    Yock, T. I.
    MacDonald, S.
    Haas-Kogan, D. A.
    Liu, K. X.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2022, 114 (03): : E487 - E488
  • [9] Hypofractionated Palliative Radiotherapy for Relapsed and Refractory High-Risk Neuroblastoma
    Koelker-Wolfe, Ellery
    Marcus, Karen J.
    Dubois, Steven G.
    Catalano, Paul J.
    Shusterman, Suzanne
    Ioakeim-Ioannidou, Myrsini
    Elhalawani, Hesham
    Yock, Torunn I.
    Macdonald, Shannon M.
    Haas-Kogan, Daphne A.
    Liu, Kevin X.
    CURRENT ONCOLOGY, 2025, 32 (03)
  • [10] Outpatient administration of naxitamab in combination with granulocyte-macrophage colony-stimulating factor in patients with refractory and/or relapsed high-risk neuroblastoma: Management of adverse events
    Mora, Jaume
    Chan, Godfrey C.
    Morgenstern, Daniel A.
    Nysom, Karsten
    Bear, Melissa K.
    Tornoe, Karen
    Kushner, Brian H.
    CANCER REPORTS, 2023, 6 (01)
12345